SPL 5B
Alternative Names: SPL-5-BLatest Information Update: 09 Mar 2023
At a glance
- Originator SpliSense
- Class Antifibrotics; Antisense oligonucleotides
- Mechanism of Action Mucin 5B expression modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 08 Feb 2023 Preclinical trials in Idiopathic pulmonary fibrosis in Israel (Inhalation) (SpliSense pipeline, February 2023)
- 08 Feb 2023 SpliSense plans a clinical trial for Idiopathic pulmonary fibrosis (Inhalation), in 2024 (SpliSense pipeline, February 2023)